Dr. Pomara has been involved in research pertaining to Alzheimer's disease (AD) and Geriatric Psychopharmacology for more than 30 years and has made many important contributions in these areas. He has been involved in many of the clinical trials that led to the FDA approval of medications currently used to treat AD. These medications include Namenda and Exelon. Dr. Pomara has made many important and original contributions in this area of study as well as to our understanding of this disease. Dr. Pomara has also received numerous grants from the National Institute of Health (NIH).
He is the author of over 100 peer-reviewed publications and has presented at various national and international scientific meetings. He is a member of numerous scientific organizations, including the American and European College of Neuropsychopharmacology.
Dr. Pomara and his research team have established a center at NKI offering treatment with the latest experimental agents for AD. Over the years, this program has enabled hundreds of patients to be safely treated with promising compounds years before they were actually introduced in the market. His participation in clinical trials is ongoing.